Boothbay Fund Management, LLC Amylyx Pharmaceuticals, Inc. Call Options Transaction History

Boothbay Fund Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$2.71 - $19.57 $195,391 - $1.41 Million	-72,100 Reduced 18.18%	324,400 $921,000
Q4 2023 Feb 14, 2024	BUY	$12.07 - $18.46 $3.07 Million - $4.69 Million	254,200 Added 178.64%	396,500 $5.84 Million
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $2.57 Million - $3.34 Million	142,300 New	142,300 $2.61 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $831,300 - $1.23 Million	30,000 New	30,000 $880,000
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $17,150 - $30,920	1,000 Added 2.29%	44,700 $1.26 Million
Q2 2022 Aug 15, 2022	BUY	$6.85 - $19.93 $91,105 - $265,069	13,300 Added 43.75%	43,700 $842,000
Q1 2022 May 16, 2022	BUY	$12.85 - $32.9 $390,640 - $1 Million	30,400 New	30,400 $391,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $234M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.